Polyneuropathies Contribute to Neurological Disability in Multiple Sclerosis
Polyneuropathies occurring in multiple sclerosis contribute to neurological disability.
Multiple Sclerosis
Serum Neurofilament Light Chain a Promising Biomarker for Monitoring MS
The serum neurofilament light chain levels were significantly higher in patients with MS with evidence of disease activity compared with patients with no evidence of disease and healthy controls.
Cortical Lesions Tracked With 7.0-T MRI Predictive of Disability in MS
Cortical lesion development surpasses white matter lesion accrual in multiple sclerosis.
Short-Course Oral Treatment Option Approved for Relapsing Forms of MS
EMD Serono announced that the Food and Drug Administration (FDA) has approved Mavenclad (cladribine) tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS).
Siponimod Approved to Treat Relapsing Forms of Multiple Sclerosis
The FDA has approved siponimod for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Traditional CV Risk Factors in MS May Not Account for Increased MI Incidence
Investigators of this retrospective study sought to compare the risk of incident AMI in patients with MS vs a matched cohort without MS, controlling for traditional cardiovascular risk factors.
Ozanimod NDA Submitted for Treatment of Relapsing Multiple Sclerosis
Celgene announced the submission of an NDA to the FDA for ozanimod for the treatment of relapsing forms of multiple sclerosis in adults.
Older Age at Puberty Linked to Decreased Multiple Sclerosis Risk
After adjustment for effects on adult BMI, correlation between age at puberty with MS was attenuated
Neighborhood-Level Socioeconomics Tied to MS Disability Progression
Lower neighborhood-level socioeconomic status (SES) is associated with a higher risk for disability progression in patients with multiple sclerosis.
Examining the Incidence of Immune Thrombocytopenia in Alemtuzumab Treatment for MS
The majority of treatment-related cases of immune thrombocytopenia can be remedied with the use of corticosteroids, platelets, or intravenous immunoglobulin.
Next post in Multiple Sclerosis
